Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01208961 · ClinicalTrials.gov registry record · Phase 2
Epanova® Compared to Lovaza® In a Pharmacokinetic, Single-dose, Evaluation
A Phase 2 study of Severe Hypertriglyceridemia, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 54
- Enrollment target
- 1
- Study location
NCT01208961 is a Phase 2 study of Severe Hypertriglyceridemia that has completed, run by AstraZeneca. The registered enrollment target is 54 participants, below the 418-participant average among 8 other Severe Hypertriglyceridemia trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01208961, a Phase 2 study of Severe Hypertriglyceridemia, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 54 participants
- Enrollment target
- 1
- Study location
Study Summary
The objectives of this study are to compare the relative bioavailabilities of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in plasma from a single dose of Epanova or Lovaza during periods of high- and low -fat consumption.
Conditions Studied
Interventions
- DRUG Epanova (4 g) and Lovaza (4 g)
- DRUG Lovaza (4 g) and Epanova (4 g)
Study Locations (1)
Illinois
- Radiant Research - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2010-09 |
| Est. Completion | 2010-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01208961
The ClinicalTrials.gov registry entry for NCT01208961 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 418-participant average among 8 other Severe Hypertriglyceridemia trials with a reported enrollment target (87% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Severe Hypertriglyceridemia appearing as the primary indexed condition, and to 2 interventions - of which Epanova (4 g) and Lovaza (4 g) is the first listed.
NCT01208961 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT01208961 about?
NCT01208961 is a clinical study titled "Epanova® Compared to Lovaza® In a Pharmacokinetic, Single-dose, Evaluation". The objectives of this study are to compare the relative bioavailabilities of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in plasma from a single dose of Epanova or Lovaza during periods of high- and low -fat consumption.
What is the current status of trial NCT01208961?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 54 participants. The study started on 2010-09. Estimated completion is 2010-11.
What conditions does trial NCT01208961 study?
This clinical trial studies the following conditions: Severe Hypertriglyceridemia.
What interventions are being tested in trial NCT01208961?
The interventions under investigation include: Epanova (4 g) and Lovaza (4 g) (DRUG), Lovaza (4 g) and Epanova (4 g) (DRUG).
Who is sponsoring clinical trial NCT01208961?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01208961 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Severe Hypertriglyceridemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia
RECRUITING · Phase 2
-
Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis
RECRUITING · Phase 3
-
CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)
ACTIVE NOT RECRUITING · Phase 3
-
To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia
ACTIVE NOT RECRUITING · Phase 3
-
Study of Plozasiran in Adults With Severe Hypertriglyceridemia
ACTIVE NOT RECRUITING · Phase 3
-
Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.